Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer
Abstract
PURPOSE: No targeted therapy combinations have achieved regulatory approval for the treatment of biomarker-positive resistance in non-small cell lung cancer (NSCLC). Given the widespread availability of next-generation sequencing (NGS) to detect resistance, we reviewed the real-world experience of using off-label targeted therapy combinations to treat advanced NSCLC at our academic safety-net hospital.
METHODS: Pharmacy records from the Hematology/Oncology Department at Boston Medical Center during the years 2017 to 2024 were reviewed. One hundred eleven patients received oral, targeted therapy during this time. Our study focused on those patients who received an off-label combination of targeted therapies for advanced NSCLC. We reviewed their demographics, treatment history, molecular data, and published evidence to support the combination.
RESULTS: Eight patients were treated with nine combination regimens. The median age was 69 years (age 29-89 years). Six patients had EGFR exon 19 deletions and two had EML4-ALK fusions. The nine combination regimens included addition of a MET inhibitor (n = 3), a RET inhibitor (n = 2), a MEK inhibitor (n = 2), an ALK inhibitor (n = 1), and an EGFR antibody (n = 1). The median duration of treatment was 7 months (range: 1-35 months), and was longest for alectinib and capmatinib (15 months ongoing and 25 months, ongoing) and gefitinib and selpercatinib (35 months, ongoing). Available supporting evidence included retrospective cohort studies…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)
- In silico and in vitro studies: investigating the chemical composition, DFT, molecular docking, and dynamic simulation of Satureja candidissima (Munby) Briq essential oil as a potential antibacterial agent
- Quercetin combined with ciprofloxacin and gentamicin inhibits biofilm formation and virulence in Staphylococcus aureus
- In silico study of the mechanism of action, pharmacokinetic and toxicological properties of some N-methylanthranilates and their analogs
- Anticonvulsant Effects of Citronellal, Daidzin, and Phytol, Possibly Through GABAA Receptor and Voltage-Gated Sodium Channel Interaction Pathways: In Vivo and In Silico Studies
- 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as D3R-Selective Ligands for 3D-QSAR, Docking and Molecular Dynamics Simulation Studies
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.